Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Belite Bio, Inc - American Depositary Shares (NQ:BLTE)

166.28 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Aug 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Belite Bio, Inc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Belite Bio Q2 Earnings Call Highlights ↗
Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the... 
Via MarketBeat
Topics Earnings
News headline image
Full Transcript: Belite Bio Q2 2026 Earnings Call ↗
Belite Bio (NASDAQ:BLTE) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by... 
Via Benzinga
Topics Earnings
News headline image
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
Belite Bio Inc - ADR (NASDAQ:BLTE) Reports Narrower-Than-Expected Q4 Loss, NDA Submission on Track for 2026 ↗
Via Chartmill
News headline image
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases ↗
Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational therapies for inherited retinal disorders could begin to reshape treatment options for Stargardt... 
Via MarketBeat
News headline image
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease ↗
Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy... 
Via MarketBeat
News headline image
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Q1 Earnings Call Highlights ↗
Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations... 
Via MarketBeat
Topics Earnings
News headline image
Belite Bio (BLTE) Q1 2026 Earnings Transcript ↗
Belite Bio (BLTE) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
From Belite Bio, Inc
Via GlobeNewswire
News headline image
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio to Participate in Four Upcoming Investor Conferences
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript ↗
Belite Bio (BLTE) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Belite Bio to Participate in the Leerink Global Healthcare Conference
From Belite Bio, Inc
Via GlobeNewswire
News headline image
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
From Belite Bio, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.